Cervical cancer is the fourth most common cancer in women worldwide, leading to over 300,000 deaths per year. Introduction of screening programs has allowed for an increased detection of precancer lesions, resulting in a 50 percent reduction of premature deaths. Yet, non-attendance rates are high: on average, 40 percent of women living in developed countries are not participating in screening, and 80 percent in developing countries. This high rate of avoidance of testing means many cases of cancer are being missed until it’s too late.

Download the white paper to learn about a user-friendly, self-sampling urine-capturing device that collects samples to be used for HPV DNA detection, from Novosanis.